VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

N/AUnknownNCT01891708

Li Liu40 enrolled

Overview

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

1. non small cell lung cancer (non squamous carcinoma) 2. ECOG 0-1 3. from 18-75 years old

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non Small Cell Lung Cancer Brain Metastasis

Interventions

bevacizumab, standard chemotherapy and radiationOTHER

the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * non squamous cell non small cell lung cancer * with measurable disease * ECOG 0-1 Exclusion Criteria: \- patients received surgery in recent 4 weeks

Locations (1)

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

RECRUITING

Outcomes

Primary Outcomes

PFS

Time frame: 6 months

Secondary Outcomes

Time frame: 18 months

Central Contacts

Li Liu, MD

CONTACT

027-85872015 liulixiehe@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.